β-Cell Function in Subjects Spanning the Range from Normal Glucose Tolerance to Overt Diabetes: A New Analysis
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The nature of the progressive beta-cell failure occurring as normal glucose tolerant (NGT) individuals progress to type 2 diabetes (T2DM) is incompletely understood. We measured insulin sensitivity (by a euglycemic insulin clamp) and insulin secretion rate (by deconvolution of plasma C-peptide levels during an oral glucose tolerance test) in 188 subjects [19 lean NGT (body mass index [BMI] </= 25 kg/m(2)), 42 obese NGT, 22 BMI-matched impaired glucose tolerance [IGT], and 105 BMI-matched T2DM]. Main determinants of beta-cell function on the oral glucose tolerance test were derived from a mathematical model featuring the following: 1) glucose concentration-insulin secretion dose response (glucose sensitivity), 2) a secretion component proportional to the derivative of plasma glucose concentration (rate sensitivity); and 3) a potentiation factor. When NGT and T2DM were subgrouped by 2-h plasma glucose concentrations, insulin secretion rate revealed an inverted U-shaped pattern, rising through NGT up to IGT and falling off thereafter. In contrast, beta-cell glucose sensitivity dropped in a monophasic, curvilinear fashion throughout the range of 2-h plasma glucose. Within the NGT range (2-h glucose of 4.1-7.7 mmol/liter), beta-cell glucose sensitivity declined by 50-70% (P < 0.02). Insulin sensitivity decreased sharply in the transition from lean to obese NGT and then declined further in IGT and mild T2DM to level off in the higher three quartiles of diabetic hyperglycemia. In T2DM, defective beta-cell potentiation and rate sensitivity also emerged (P </= 0.05). In the whole data set, insulin sensitivity and the dynamic parameters of beta-cell function explained 89% of the variability of 2-h plasma glucose levels. The following conclusions were reached: 1) beta-cell glucose sensitivity falls already within the NGT range in association with rising 2-h plasma glucose concentrations, although absolute insulin secretion rates increase; and 2) throughout the glucose tolerance range, dynamic parameters of beta-cell function (glucose sensitivity, rate sensitivity, and potentiation) and insulin sensitivity are independent determinants of 2-h plasma glucose levels.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The slope of the relationship between glucose and insulin secretion (ie, β -CGS) is a major controller of postprandial glu cose levels (23, 24).”
From Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test (2024) · cites this paper as [24]
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Self-citationInsulin signalling and the regulation of glucose and lipid metabolism
Saltiel, A. R., & Kahn, C. R. (2001) · Nature · doi:10.1038/414799a · Cited by 5,326
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940 · cited 2×
“5] -cell glucose sensitivity (pmol min 1 m 2 mM (1)) 147 [97] 92 [98] 55 [34] 14 [15]”
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
McGarry, J. D. (2002) · Diabetes · doi:10.2337/diabetes.51.1.7 · Cited by 1,435
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405
Martin, B. C., Warram, J. H., Krolewski, A. S., Soeldner, J. S., Kahn, C. R., Martin, B. C., & Bergman, R. N. (1992) · The Lancet · doi:10.1016/0140-6736(92)92814-v · Cited by 1,158
Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications
Unger, R. H. (1995) · Diabetes · doi:10.2337/diab.44.8.863 · Cited by 1,100
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“Fasting plasma insulin (pmol/liter) 20 [16] 48 [32] 74 [47] 94 [58] Insulin AUC (nmol/liter h) 22 [15] 45 [38] 65 [33] 24 [23] I/ G (pmol/mmol) 73 [84] 163 [172] 122 [140] 19 [33] Fasting ISR (pmol/min m (2)) 53 [34] 85 [53] 116 [39] 112 [71] Total IS (nmol m (2)) 30 [18] 43 [19] 47 [17] 24 [19] Insulin sensitivity (M…”
Cited by
Items 201–300 of 538
Predicting the 20‐year diabetes incidence rate
Dankner, R., Abdul‐Ghani, M. A., Gerber, Y., Chetrit, A., Wainstein, J., & Raz, I. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.728 · Cited by 42
“Impaired pancreatic β-cell function and whole-body insulin insensitivity were found to be independent predictors for elevated 2-h plasma glucose levels [13].”
BackgroundModulation of β‐cell function: a translational journey from the bench to the bedside
Goldfine, A. B., & Kulkarni, R. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01647.x · Cited by 45
Lipid Droplets’ Role in the Regulation of β-Cell Function and β-Cell Demise in Type 2 Diabetes
Tong, X., Liu, S., Stein, R. W., & Imai, Y. (2022) · Endocrinology · doi:10.1210/endocr/bqac007 · Cited by 44
Mari, A., Bagger, J. I., Ferrannini, E., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073154 · Cited by 40
“Glucose sensitivity (pmolminmLmmol(21)) 39 [22] 41 [30] 34 [24] 68 [40] 93 [23] 116 [31]”
BackgroundSelf-citationSalinari, S., Carr, R. D., Guidone, C., BERTUZZI, A., Cercone, S., Riccioni, M. E., Manto, A., Ghirlanda, G., & Mingrone, G. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00559.2012 · Cited by 42
Maki, K. C., Nieman, K. M., Schild, A. L., Kaden, V. N., Lawless, A. L., Kelley, K., & Rains, T. M. (2015) · Journal of Nutrition · doi:10.3945/jn.114.204503 · Cited by 47
Henquin, J.-C., Ibrahim, M. M., & Rahier, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-10296-z · Cited by 40
Metabolic syndrome: controversial but useful.
Stolar, M. J. (2007) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.74.3.199 · Cited by 41
Maghbooli, Z., Hossein‐Nezhad, A., Mirzaei, K., Karimi, F., Besharati, A., Omidfar, K., & Larijani, B. A. (2010) · Reproductive Sciences · doi:10.1177/1933719109351097 · Cited by 41
Treatment of Type 2 Diabetes With Combined Therapy
Massi‐Benedetti, M., & Orsini-Federici, M. (2008) · Diabetes Care · doi:10.2337/dc08-s233 · Cited by 44
Martono, D. P., Lub, R., Heerspink, H. J. L., Hak, E., Wilffert, B., & Denig, P. (2015) · Diabetic Medicine · doi:10.1111/dme.12688 · Cited by 39
Postprandial Insulin Response and Clearance Among Black and White Women: The Federal Women’s Study
Chung, S. T., Cruz, M. G. L., Aldana, P. C., Mabundo, L. S., DuBose, C. W., Onuzuruike, A. U., Walter, M. F., Gharib, A. M., Courville, A. B., Sherman, A., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01032 · Cited by 219
Omori, K., Nakamura, A., Miyoshi, H., Takahashi, K., Kitao, N., Nomoto, H., Kameda, H., Cho, K. Y., Takagi, R., Hatanaka, K. C., et al. (2019) · Metabolism · doi:10.1016/j.metabol.2019.06.006 · Cited by 42
Xiang, A. H., Trigo, E., Martinez, M., Katkhouda, N., Beale, E., Wang, X., Wu, J., Chow, T., Montgomery, C., Nayak, K. S., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1662 · Cited by 37
Fetal Exposure to Cannabis and Childhood Metabolic Outcomes: The Healthy Start Study
Moore, B. F., Sauder, K. A., Shapiro, A. L. B., Crume, T., Kinney, G. L., & Dabelea, D. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac101 · Cited by 36
Impaired β‐cell function in lean normotolerant former gestational diabetic women
Tura, A., Mari, A., Winzer, C., Kautzky‐Willer, A., & Pacini, G. (2005) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2006.01587.x · Cited by 38
Self-citationRapid Deterioration of Insulin Secretion in Obese Adolescents Preceding the Onset of Type 2 Diabetes
Elder, D. A., Hornung, L. N., Herbers, P. M., Prigeon, R. L., Woo, J. G., & D’Alessio, D. A. (2014) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2014.11.029 · Cited by 44
Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
Fadini, G. P., & Rigato, M. (2014) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s37644 · Cited by 36
“The pathogenesis of type 2 diabetes is the consequence of a progressive loss of pancreatic beta cell function combined with increasing peripheral insulin resistance.(10) It has been estimated that only 50% of normal beta cell function is still present at the time of diagnosis.”
BackgroundPathogenetic Mechanisms and Cardiovascular Risk
Bianchi, C., Miccoli, R., Bonadonna, R. C., Giorgino, F., Frontoni, S., Faloia, E., Marchesini, G., Dolci, M. A., Cavalot, F. L., Cavallo, M. G., et al. (2012) · Diabetes Care · doi:10.2337/dc11-2504 · Cited by 41
GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus
Manaithiya, A., Alam, O., Sharma, V., Naim, M. J., Mittal, S., & Khan, I. A. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104998 · Cited by 39
Mather, K. J., Mari, A., Heise, T., DeVries, J. H., Hua, M., Urva, S., Coskun, T., Haupt, A., Heine, R. J., Pratt, E., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae319 · Cited by 35
Self-citationPerl, S., Schmoelzer, I., Sourij, H., Pressl, H., Eder, M., Zweiker, R., & Wascher, T. C. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.10.048 · Cited by 35
Armato, J., DeFronzo, R. A., Abdul-Ghani, M., & Ruby, R. (2012) · Endocrine Practice · doi:10.4158/ep11194.or · Cited by 35
Self-citationAnti-diabetic medications: How to make a choice?
Babiker, A. M. I., & Dubayee, M. A. (2017) · Sudanese Journal of Paediatrics · doi:10.24911/sjp.2017.2.12 · Cited by 51
Koivula, R. W., Forgie, I. M., Kurbasic, A., Viñuela, A., Heggie, A. J., Giordano, G. N., Hansen, T. H., Hudson, M., Koopman, A. D. M., Rutters, F., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-4906-1 · Cited by 41
Self-citationImpaired Insulin Action Is Associated With Increased Glucagon Concentrations in Nondiabetic Humans
Sharma, A., Varghese, R. T., Shah, M., Man, C. D., Cobelli, C., Rizza, R. A., Bailey, K. R., & Vella, A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01197 · Cited by 35
High Resolution Clinical Model-Based Assessment of Insulin Sensitivity
Lotz, T. (2007) · UC Research Repository (University of Canterbury) · doi:10.26021/2196 · Cited by 39
Toh, D. W. K., Koh, E. S., & Kim, J. E. (2020) · Nutrition · doi:10.1016/j.nut.2019.110634 · Cited by 34
The Disposition Index Does Not Reflect β-Cell Function in IGT Subjects Treated With Pioglitazone
DeFronzo, R. A., Tripathy, D., Abdul-Ghani, M., Musi, N., & Gastaldelli, A. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1515 · Cited by 34
Self-citationThe importance of β-cell management in type 2 diabetes
Standl, E. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01360.x · Cited by 39
Kanbay, M., Çöpür, S., Topçu, A. U., Güldan, M., Özbek, L., Gaipov, A., Ferro, C. J., Cozzolino, M. G., Cherney, D. Z. I., & Tuttle, K. R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15575 · Cited by 36
“58”
What Is Gestational Diabetes—Really?
Buchanan, T. A., Xiang, A. H., Page, K. A., & Watanabe, R. M. (2025) · Diabetes · doi:10.2337/dbi24-0041 · Cited by 31
Bizzotto, R., Tricò, D., Natali, A., Gastaldelli, A., Muscelli, E., Fronzo, R. A. D., Arslanian, S. A., Ferrannini, E., & Mari, A. (2021) · Diabetes Care · doi:10.2337/dc21-0545 · Cited by 31
Self-citationGlycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances
Khunti, K., & Davies, M. J. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01186.x · Cited by 34
“Insulin resistance, which increases as individuals progress from normal glucose tolerance through impaired glucose tolerance (IGT) to diabetes, also plays a part in the development of the condition [25,26].”
BackgroundPrediabetes: To treat or not to treat?
Moutzouri, E., Tsimihodimos, V., Rizos, E. C., & Elisaf, M. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.10.007 · Cited by 36
Clinical Measures of Islet Function: Usefulness to Characterize Defects in Diabetes
Åhrén, B., Pratley, R. E., Soubt, M., Dunning, B. E., & Foley, J. E. (2008) · Current Diabetes Reviews · doi:10.2174/157339908784220714 · Cited by 32
Update on Nonautoimmune Diabetes in Children
Zeitler, P. S. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0493 · Cited by 34
Fasting‐based Estimates of Insulin Sensitivity in Overweight and Obesity: A Critical Appraisal
Ruige, J. B., Mertens, I. L., Bartholomeeusen, E., Dirinck, E. L., Ferrannini, E., & Gaal, L. F. V. (2006) · Obesity · doi:10.1038/oby.2006.142 · Cited by 33
Self-citation(ESC), G. D. T. S. D. Y. E. C. D. L. S. E. D. C., & (EASD), D. L. S. E. P. E. E. D. L. D. (2007) · Revista Española de Cardiología · doi:10.1016/s0300-8932(07)75070-4 · Cited by 30
Therapeutic Approaches for Preserving or Restoring Pancreatic β-Cell Function and Mass
Jung, K. Y., Kim, K. M., & Lim, S. K. (2014) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2014.38.6.426 · Cited by 34
“In general, pancreatic β-cell functions decrease up to approximately 50% of normal at the time of diagnosis of T2DM [2].”
Rasouli, N., Spencer, H. J., Rashidi, A. A., & Elbein, S. C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0919 · Cited by 31
“(34), although AIRg was a sensitive measure in the studies of Byrne et al.”
BackgroundResultLópez, X., Cypess, A. M., Manning, R., O'Shea, S., Kulkarni, R., & Goldfine, A. B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0627 · Cited by 30
Heianza, Y., Arase, Y., Fujihara, K., Tsuji, H., Saito, K., Hsieh, S. D., Kodama, S., Shimano, H., Yamada, N., Hara, S., et al. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03667.x · Cited by 30
Tripathy, D., Cobb, J. E., Gall, W., Adam, K., George, T., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3824 · Cited by 30
Self-citationβ-Cell Function in Mild Type 2 Diabetic Patients
Mari, A., Gastaldelli, A., Foley, J. E., Pratley, R. E., & Ferrannini, E. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1132 · Cited by 28
Self-citationValidation of insulin secretion indices in cystic fibrosis patients
Hammana, I., Potvin, S., Tardif, A., Berthiaume, Y., Coderre, L., & RABASA-LHORET, R. P. R. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2009.08.007 · Cited by 28
“Numerous indices derived from fasting or oral glucose tolerance test (OGTT) values have been proposed to evaluate insulin secretion [11–13].”
Glitazonas e síndrome metabólica: mecanismos de ação, fisiopatologia e indicações terapêuticas
Gomes, M. B. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000200013 · Cited by 40
Pan, R., Xu, T., Bai, J., Xia, S., Liu, Q., Li, J., Xiao, X., & Dong, Y. (2020) · Journal of Food Biochemistry · doi:10.1111/jfbc.13471 · Cited by 35
Guardado‐Mendoza, R., Jiménez-Ceja, L. M., Majluf‐Cruz, A., Kamath, S., Fiorentino, T. V., Casiraghi, F., Velazquez, A. O. C., DeFronzo, R. A., Dick, E. J., Davalli, A. M., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.205 · Cited by 28
“In normoglycemic obese individuals a compensatory increase in insulin secretion maintains normal glucose levels (8, 10, 17).”
Self-citationHamley, S., Kloosterman, D., Duthie, T., Man, C. D., VISENTIN, R., Mason, S. A., Ang, T., Selathurai, A., Kaur, G., Morales-Scholz, M. G., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-04990-y · Cited by 32
Chen, M. E., Chandramouli, A. G., Considine, R. V., Hannon, T. S., & Mather, K. J. (2018) · Diabetes Care · doi:10.2337/dc17-1373 · Cited by 26
“Prior longitudinal studies in adolescents have localized b-cell dysfunction to dynamic secretion in adolescents (26), whereas the dominance of dynamic or static secretory dysfunction in adults is less clear (7,9)”
BackgroundAdams, J. D., Man, C. D., LAURENTI, M. C., Andrade, M. D. H., Cobelli, C., Rizza, R. A., Bailey, K. R., & Vella, A. V. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154175 · Cited by 26
Quantifying beta cell function in the preclinical stages of type 1 diabetes
Galderisi, A., Carr, A. L. J., Martino, M., Taylor, P., Senior, P. A., & Dayan, C. M. (2023) · Diabetologia · doi:10.1007/s00125-023-06011-5 · Cited by 32
“…of glucose, insulin and C-peptide kinetics have been proposed [12, 35, 81, 82], here we focus on Cobelli’s oral minimal model [83] and Mari’s model [82] because of their large validation in different age groups, including paediatric cohorts [5, 84], and wide use over the last few decades [35, 79,…”
MethodDoiron, B., Hu, W., Norton, L., & DeFronzo, R. A. (2012) · Diabetologia · doi:10.1007/s00125-011-2414-z · Cited by 28
Self-citationPreservation of Beta-Cell Function in Type 2 Diabetes
Nyalakonda, K., Sharma, T., & Ismail‐Beigi, F. (2010) · Endocrine Practice · doi:10.4158/ep10112.ra · Cited by 27
Latulippe, M. E., Méheust, A., Augustin, L. S. A., Benton, D., Berčík, P., Birkett, A. M., Eldridge, A. L., Faintuch, J., Hoffmann, C., Jones, J. M., et al. (2013) · Food & Nutrition Research · doi:10.3402/fnr.v57i0.19214 · Cited by 28
“7 mmol/L) 2 hours after the glucose challenge compared to the lower end of normal (51), suggesting not only a greater risk of developing diabetes in the future but also that low GI foods may be of benefit over larger glucose loads delivered by high GI foods, in these metabolically challenged individuals.”
BackgroundChamarthi, B., & Cincotta, A. H. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1315290 · Cited by 25
“The natural progression of disease in type 2 diabetes mellitus (T2DM) is marked by progressive decline in pancreatic betacell function resulting in the need for exogenous insulin therapy in a large proportion of patients, particularly with increasing duration of the disease [1].”
BackgroundUtzschneider, K. M., Tripputi, M. T., Kozedub, A., Mather, K. J., Nadeau, K. J., Edelstein, S. L., Hannon, T. S., Arslanian, S. A., Cree‐Green, M., Buchanan, T. A., et al. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13113 · Cited by 25
“In both youth and adults, as glycemic status declines from normal glucose tolerance to IGT to type 2 diabetes, insulin secretion adjusted for insulin sensitivity declines and glucose sensitivity and rate sensitivity diminish.(16,17) No study outside of RISE has directly compared β-cell function between youth and adult…”
BackgroundSelf-citationMari, A., Gastaldelli, A., Natali, A., Østergård, T., Schmitz, O., & Ferrannini, E. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00175.2004 · Cited by 25
Self-citationThe incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact?
Aulinger, B. A., Vahl, T. P., Prigeon, R. L., D'Alessio, D. A., & Elder, D. A. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00496.2015 · Cited by 24
Type 1 diabetes mellitus in pediatric age group: A rising endemic
Pasi, R., & Ravi, K. S. (2022) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_975_21 · Cited by 33
Tura, A., Mari, A., Prikoszovich, T., Pacini, G., & Kautzky‐Willer, A. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03178.x · Cited by 25
Self-citationGastaldelli, A., Brodows, R. G., & D'Alessio, D. (2014) · Clinical Endocrinology · doi:10.1111/cen.12199 · Cited by 24
Self-citationFu, J., Githaka, J. M., Dai, X.-Q., Plummer, G., Suzuki, K., Spigelman, A. F., Bautista, A., Kim, R., Greitzer-Antes, D., Fox, J. E. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127896 · Cited by 30
What are the pharmacotherapy options for treating prediabetes?
Daniele, G., Abdul‐Ghani, M. A., & DeFronzo, R. A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.944160 · Cited by 26
“Studies from our group and others have demonstrated that the primary defect in IGT and T2DM is an inability of the b-cell to respond to glucose [26,34], and this b-cell ‘blindness’ to glucose, at least in part, can be restored by incretin hormones [120].”
BackgroundInfluentialSelf-citationPathogenesis of Type 2 Diabetes Mellitus
Leahy, J. L. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-043-4_2 · Cited by 32
Tura, A., Pacini, G., Kautzky‐Willer, A., Gastaldelli, A., DeFronzo, R. A., Ferrannini, E., & Mari, A. (2011) · Metabolism · doi:10.1016/j.metabol.2011.08.001 · Cited by 23
“These subjects have been included in a previous study [7].”
BackgroundSelf-citationden Biggelaar, L. J. C. J., Sep, S. J. S., Mari, A., Ferrannini, E., DONGEN, M. C. J. M. V., Wijckmans, N. E. G., Schram, M. T., Kallen, C., Schaper, N. C., Henry, R. M. A., et al. (2019) · European Journal of Nutrition · doi:10.1007/s00394-019-02026-0 · Cited by 30
Self-citationBi, Y., Zeng, L., Zhu, D., Yan, J. Y., Zhang, Y., Tong, G., Mu, P., Shen, S., Hu, Y., Yu, Q., et al. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01504.x · Cited by 21
DNA methylation of microRNA-375 in impaired glucose tolerance
Wang, X., Chang, X., Li, J., YIN, L., & Sun, K. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.1816 · Cited by 24
Impact of Major Depressive Disorder on Prediabetes by Impairing Insulin Sensitivity
Shelton, R. C., & Li, L. (2016) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000664 · Cited by 23
“adults will suffer from MDD at some point in their lives [7].”
BackgroundInsulin Secretion and Insulin Sensitivity in Relation to Fasting Glucose in Healthy Subjects
Åhrén, B. (2007) · Diabetes Care · doi:10.2337/dc06-1759 · Cited by 22
Regulation of Intermediary Metabolism During Fasting and Feeding
DeFronzo, R. A., & Ferrannini, E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00035-4 · Cited by 26
Self-citationLi, L., Garvey, W. T., & Gower, B. A. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00151 · Cited by 21
Beaudry, K. M., Surdi, J. C., Mari, A., & Devries, M. C. (2022) · Physiological Reports · doi:10.14814/phy2.15354 · Cited by 24
“Thus, enhanced insulin clearance may represent a key mechanism by which exercise reduces insulinemia and prevents the development of IR and T2D.”
BackgroundInfluentialSelf-citationβ-Cell Dysfunction in Adolescents and Adults with Newly Diagnosed Type 2 Diabetes Mellitus
Elder, D. A., Herbers, P. M., Weis, T., Standiford, D. A., Woo, J. G., & D’Alessio, D. A. (2012) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2011.12.002 · Cited by 22
He, L., He, M., Lv, X., Pu, D., Su, P., & Liu, Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.06.016 · Cited by 23
“Insulin resistance (IR) [1] and insulin deficiency [2] are the two major pathophysiological causes of type 2 diabetes (T2DM) [3,4].”
BackgroundRETRACTED: Mitochondrial pathophysiology and type 2 diabetes mellitus
García-Rovés, P. M. (2011) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2011.584538 · Cited by 27
RetractedA Spectrum of Dynamic Insulin Sensitivity Test Protocols
Docherty, P. D., Chase, J. G., Morenga, L. T., Lotz, T., Berkeley, J. E., Shaw, G. M., McAuley, K. A., & Mann, J. I. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500626 · Cited by 23
Surdacki, A., Stochmal, E., Szurkowska, M., Bode‐Böger, S. M., Martens‐Lobenhoffer, J., Stochmal, A., Klecha, A., Kawecka−Jaszcz, K., Dubiel, J. S., Huszno, B., et al. (2006) · Metabolism · doi:10.1016/j.metabol.2006.08.023 · Cited by 23
Implications of the cGAS-STING pathway in diabetes: Risk factors and therapeutic strategies
Mohammadi, S., & Khorasani, M. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134210 · Cited by 22
Roe, E. D., Chamarthi, B., & Raskin, P. (2015) · Journal of Diabetes Research · doi:10.1155/2015/834903 · Cited by 22
“…2 diabetes mellitus (T2DM) patients typically becomes progressively more difficult as the duration of disease lengthens as a result of continuing decline in the capacity of the pancreatic beta cells for appropriate glucose stimulated insulin release, in the presence of insulin resistance [1, 2].”
BackgroundYu, L. J., Feng, D., Esangbedo, I. C., Zhao, Y., Han, L., Zhu, Y., Fu, J., Li, G., Wang, D., Wang, Y., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000724 · Cited by 21
Jones, A. G., Besser, R. E. J., Shields, B. M., McDonald, T. J., Hope, S. V., Knight, B., & Hattersley, A. T. (2012) · BMC Endocrine Disorders · doi:10.1186/1472-6823-12-6 · Cited by 20
“secretion have higher glucose increment after oral glucose tolerance test and higher glycaemic variability [27,28].”
BackgroundNowotny, B., KAHL, S., Klüppelholz, B., Hoffmann, B. H., Giani, G., Livingstone, R. S., Nowotny, P., Stamm, V., Herder, C., Tura, A., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.12.005 · Cited by 21
Effectiveness of carbohydrates as a functional ingredient in glycemic control
Sardá, F. A. H., Giuntini, E. B., Nazare, J., König, D., Bahia, L., Lajolo, F. M., & de Menezes, E. W. (2018) · Food Science and Technology · doi:10.1590/fst.42517 · Cited by 30
Peters, A., Sprengell, M., & Kubera, B. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104847 · Cited by 20
Shaefer, C. F., Reid, T., DAILEY, G. E., Mabrey, M., Vlajnic, A., Stuhr, A., Stewart, J. A., & Zhou, R. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.10.2824 · Cited by 19
Choice of early treatment regimen and impact on β-cell preservation in type 2 diabetes
Mudaliar, S. R. D. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12154 · Cited by 19
Insulin Therapy for Pre-Hyperglycemic Beta-Cell Endoplasmic Reticulum Crowding
Absood, A., Gandomani, B. S., Zaki, A. L., Nasta, V., Michail, A., Habib, P. M. W., & Hodish, I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054351 · Cited by 18
“Likewise, insulin sensitivity is not necessarily higher in patients with diabetes, compared to non-diabetic obese [45], indicating that obesity and insulin resistance likely function as environmental stressors to genuinely defective b-cells in genetically predisposed individuals.”
BackgroundPretty, C. G. (2012) · UC Research Repository (University of Canterbury) · doi:10.26021/2015 · Cited by 23
Rong, L., Luo, N., Gong, Y., Tian, H., Sun, B., & Li, C. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108683 · Cited by 19
High-Intensity Exercise Training for the Prevention of Type 2 Diabetes Mellitus
Rynders, C. A., & WELTMAN, A. L. (2014) · The Physician and Sportsmedicine · doi:10.3810/psm.2014.02.2042 · Cited by 20
den Biggelaar, L. J. C. J., Eussen, S. J. P. M., Sep, S. J. S., Mari, A., Ferrannini, E., DONGEN, M. C. J. M. V., Denissen, K. F. M., Wijckmans, N. E. G., Schram, M. T., Kallen, C., et al. (2017) · Nutrients · doi:10.3390/nu9040380 · Cited by 22
“If insulin sensitivity decreases, pancreatic β-cells normally upregulate insulin secretion in order to maintain normal blood glucose levels [13,14].”
BackgroundSelf-citationDekker, J. M., & Balkau, B. (2006) · Diabetes Care · doi:10.2337/dc05-2220 · Cited by 21
“In addition, it is now clear that IFG and IGT reflect different physiological processes (22) that occur in different subjects and that differ with respect to their association with CVD (6,7).”
BackgroundTjandrawinata, R. R., Manaf, A., Malinda, D., & Susanto, L. W. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s97568 · Cited by 19
“Another study by Ferrannini et al 31 and Gastaldelli et al 32 demonstrated that improvement of insulin sensitivity by insulin sensitizers was associated with a decline in plasma insulin response.”
Antić, I. B., Ilic, D. S., Bjekić-Macut, J., Bogavac, T., Milutinović, D. V., Kastratović-Kotlica, B., Milic, N. M., Stanojlović, O. P., Andric, Z. G., & Μacut, D. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0775 · Cited by 21
Advances in Epidemiology and Treatment of Type 2 Diabetes in Children
Pinhas‐Hamiel, O., & Zeitler, P. S. (2005) · Advances in Pediatrics · doi:10.1016/j.yapd.2005.03.008 · Cited by 20
Evaluating insulin secretagogues in a humanized mouse model with functional human islets
Luo, J., Nguyen, K., Chen, M., TRAN, T. L., Hao, J., Tian, B., Rulifson, I. C., Zhang, Y., Tian, L., Zhang, Y., et al. (2012) · Metabolism · doi:10.1016/j.metabol.2012.07.010 · Cited by 17
“[4] Ferrannini E, Gastaldelli A, Miyazaki Y, et al.”
BackgroundMechanisms Underlying the Pathogenesis of Isolated Impaired Glucose Tolerance in Humans
Varghese, R. T., Man, C. D., Sharma, A. R., Viegas, I., Barosa, C., Marques, C., Shah, M., Miles, J. M., Rizza, R. A., Jones, J. G., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1998 · Cited by 17
“In contrast, Ferrannini et al (31) reported that compared to matched obese subjects with NGT, subjects with IGT are less insulin sensitive but exhibit similar -cell secretory indices.”
Metadata
- Authors
- Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A.
- Affiliations
- University of Pisa (IT)
- The University of Texas at San Antonio Health Science Center (US)
- National Research Council (IT)
- Corresponding author
- Ferrannini, Ele
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-01
- Volume
- 90
- Issue
- 1
- Pages
- 493-500
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1981581852
- Semantic Scholar
- 1e59c003bc095926431f049735ca1064ebb24a32
- Cited by
- 540
- References
- 45
- Citations by year
- 2026: 10 · 2025: 21 · 2024: 20 · 2023: 20 · 2022: 27 · 2021: 19 · 2020: 21 · 2019: 22 · 2018: 25 · 2017: 26 · 2016: 21 · 2015: 33 · 2014: 33 · 2013: 26 · 2012: 32
- FWCI
- 29.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 24092)
- National Center for Research Resources (M01RR01346, M01RR001346)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- beta-cell function, type 2 diabetes, impaired glucose tolerance, insulin sensitivity, insulin secretion rate, beta-cell glucose sensitivity, rate dependence, C-peptide, hyperinsulinemic-euglycemic clamp, oral glucose tolerance test, obesity, 2-hour plasma glucose
- MeSH terms
- Insulin Secretion, Adult, Blood Glucose, Cross-Sectional Studies, Diabetes Mellitus, Fatty Acids, Nonesterified, Female, Glucose Tolerance Test, Humans, Insulin, Insulin Resistance, Islets of Langerhans, Male, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.